Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HTA bodies eager for EMA disclosure of clinical trial data

This article was originally published in SRA

Executive Summary

It's not only competitors and independent researchers that are keeping a watchful eye on EU plans to require the disclosure of full clinical trial data on new drugs. Health technology assessment (HTA) bodies such as Germany's IQWiG are closely monitoring developments on this front, and are particularly keen to see the clinical trial reports that the European Medicines Agency proposes to publish proactively from January next year.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS117367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel